Decreased expression of the Augmenter of Liver Regeneration results in increased apoptosis and oxidative damage in human-derived glioma cells by Polimeno, L et al.
Decreased expression of the Augmenter of Liver
Regeneration results in increased apoptosis and
oxidative damage in human-derived glioma cells
L Polimeno*
,1,2,3, B Pesetti
2, F De Santis
4, L Resta
5, R Rossi
5, A De Palma
4, B Girardi
5, A Amoruso
1,3 and A Francavilla
2
The mammalian growth factor erv1-like (GFER) gene encodes a sulfhydryl oxidase enzyme, named Augmenter of Liver
Regeneration (ALR). Recently it has been demonstrated that ALR supports cell proliferation acting as an anti-apoptotic factor.
This effect is determined by ALR ability to support the anti-apoptotic gene expression and to preserve cellular normoxic
conditions. We recently demonstrated that the addition of recombinant ALR (rALR) in the culture medium of H2O2-treated
neuroblastoma cells reduces the lethal effects induced by the hydrogen peroxide. Similar data have been reported in the
regenerating liver tissue from partially hepatectomized rats treated with rALR. The purpose of the present study was to evaluate
the effect of the GFER inhibition, via the degradation of the complementary mRNA by the speciﬁc siRNA, on the behaviour of the
apoptosis (apoptotic gene and caspase expression and apoptotic cell number) and of the oxidative stress-induced parameters
(reactive oxygen species (ROS), clusterin expression and mitochondrial integrity) in T98G glioma cells. The results revealed a
reductionof(i)ALR,(ii)clusterinand(iii)bcl-2andanincreaseof(iv)caspase-9,activatedcaspase-3,ROS,apoptoticcellnumber
and mitochondrial degeneration. These data conﬁrm the anti-apoptotic role of ALR and its anti-oxidative properties, and shed
some light on the molecular pathways through which ALR modulates its biological effects.
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Gliomas represent the most frequently diagnosed tumours of
the central nervous system. With a highly invasive phenotype,
gliomas diffusely inﬁltrate into various regions of the brain,
1,2
rendering their surgical resection impossible; therefore, the
prognosisforpatientswithgliomasispooreveninresponseto
multidisciplinary treatment.
3
Augmenter of Liver Regeneration (ALR), a sulfhydryl
oxidase enzyme
4 encoded by the growth factor erv1-like
(GFER) gene, is present in all mammalian cells
5–7 and,
compared with tissues from healthy subjects, is signiﬁcantly
overexpressed in tissues of patients affected by cell-prolifer-
ating diseases, such as hepatocellular carcinoma (HCC),
chronic hepatitis (CH), cholangiocellular carcinoma
8 or in
regenerating liver after partial hepatectomy in rats.
9,10 We
recently demonstrated that ALR protects human-derived
neuroblastoma cells from H2O2-induced apoptosis, reducing
mitochondrial swelling, cell death and apoptotic cell number,
inhibiting cytochrome-c mitochondrial release and upregulat-
ing the bcl-2/bax gene-transcription protein ratio. Similar data
are reported in the literature in different experimental models,
in vivo and in vitro.
11–15
Various reports reveal that a defective or inefﬁcient
apoptosis is an acquired hallmark of cancer cells,
16 which
renders any pharmacological treatment almost ineffective.
17
Apoptosis is characterized by two different molecular
pathways: (i) the extrinsic pathway, which is triggered by
the presence of transmembrane death receptors (Fas, TNF
receptor and TRAIL receptors) and their respective ligands on
cellular membranes and (ii) the intrinsic pathway, known as
mitochondrial apoptosis, which requires the disruption of the
mitochondrial outer membrane and leads to the apoptotic
caspase cascade.
18 Mitochondrial apoptosis is regulated by
the anti-apoptotic bcl-2 family of proteins, which prevents
mitochondrial swelling.
In the present study, in human-derived glioma cells, we
investigated the effect of GFER silencing, by speciﬁc siRNA,
on apoptotic gene expression, caspase-9 and activated
caspase-3expression,apoptoticcellnumber,reactiveoxygen
Received 06.10.11; revised 06.2.12; accepted 08.2.12; Edited by A Stephanou
1SectionofGastroenterology,DepartmentofEmergencyandOrganTransplantation(DETO),UniversityofBari,Bari,Italy;
2IRCCS‘S.deBellis’,CastellanaGrotte,Bari,
Italy;
3Center Interdepartment of Research on Gastroenterology and Hepatology of Age of Development (CIRGEEE), University of Bari, Bari, Italy;
4Department of
Bioscience, Biotechnology and Pharmacological Sciences, University of Bari, Bari, Italy and
5Section of Anatomy Pathology, Department DAP, University of Bari, Bari,
Italy
*Corresponding author: L Polimeno, Section of Gastroenterology, Department of Emergency and Organ Transplantation (DETO), University of Bari, Policlinico, Piazza
G. Cesare, 11, 70124 Bari, Italy. Tel: þ39 80 5592825; Fax: þ39 80 5478641; E-mail: l.polimeno@gastro.uniba.it
Keywords: oxidative stress; ROS; apoptosis; mitochondrial protection
Abbreviations: ALR, Augmenter of Liver Regeneration; rALR, recombinant ALR; GFER, growth factor erv1-like; PBS, phosphate buffer saline; FBS, foetal bovine
serum; ROS, reactive oxygen species; siRNA, small interfering RNA; TNFR, tumour necrosis-factor receptor; TRAIL, tumour necrosis factor-related apoptosis inducing
ligand receptors; HSS, hepatic stimulatory substance; HCC, hepatocellular carcinoma; CH, chronic hepatitis; 7-AAD, 7-aminoactinomycin D; EDTA, ethylene diamine
tetra acetate; SDS, sodium dodecyl sulphate; IGEPAL, octylphenoxypolyethoxyethanol; IMS, intermembrane space; OXPHOS, oxidative phosphorylation; mtTFA,
mitochondrial transcription factor A; PH, partial hepatectomy; PFA, paraformaldehyde; BSA, bovine serum albumin; HRP, horseradish peroxidase; DCFH-DA,
27-dichloroﬂuorescin diacetate; LPO, lipid peroxidation; Mia40, mitochondrial intermembrane space import and assembly protein 40
Citation: Cell Death and Disease (2012) 3, e289; doi:10.1038/cddis.2012.25
& 2012 Macmillan Publishers Limited All rights reserved 2041-4889/12
www.nature.com/cddisspecies (ROS) levels, clusterin expression and mitochondrial
morphology.
Results
H2O2-induced oxidative stress. Figure 1 reports the
behaviour of H2O2-induced ROS in glioma cells maintained
in cell culture and the effect of the increasing doses of
recombinant ALR (rALR) to the culture medium. We have
previously and broadly described the effects of ALR both on
apoptosis and on the endocellular redox state altered by
H2O2 addition in cell culture of neuroblastoma cells.
12 In our
present experimental conditions, a ﬁve- to six-fold increase,
statistically signiﬁcant (P¼3.7 10
 5), of ROS levels
was registered in H2O2-treated cells compared with H2O2-
untreated cells. The presence of increasing doses of rALR in
the culture medium counteracted the effect induced by H2O2.
Effect of GFER silencing
ALR expression. Figure 2 reports ALR expression in siRNA/
ALR-treated cells and control cells evaluated both using
western blot analysis (Figure 2a) and confocal microscopy
(Figure 2b). The western blot analysis revealed the presence
of two forms of the protein, one of 21 and one of 23 kDa,
10
markedly reduced in siRNA/ALR-treated cells compared with
control cells (Figure 2a, upper-right). The normalization of ALR
expression, with respect to b-actin level, revealed a
statistically signiﬁcant (P¼6.7 10
 5) reduction of ALR in
siRNA/ALR-treated cells compared with control cells. The
confocal microscopy immunodetection revealed a
considerable presence of ALR in control cells, which
resulted signiﬁcantly reduced in siRNA/ALR-treated cells
(Figure 2b). For each determination, the nuclear
identiﬁcation, evidenced by TO-PRO-3 (Invitrogen srl, Milan,
Italy), the speciﬁc ALR immunodetection, revealed by Alexa
Fluor 488 (Invitrogen srl), and the ‘merge’ are reported.
Clusterin expression. Figure 3 reports the clusterin
expression in siRNA/ALR-treated and control glioma cells
evaluated using western blot analysis (Figure 3a) and
confocal microscopy (Figure 3b). A marked reduction of
clusterin in siRNA/ALR-treated cells, compared with
control cells, was evidenced (Figure 3a, upper-right). The
normalization of clusterin expression, compared with b-actin
level, revealed a statistically signiﬁcant (P¼5.4 10
 3)
reduction of the protein. Clusterin immunodetection using
confocal microscopy revealed a considerable amount
of this factor in the cytosol of control glioma cells, which
dramatically reduced in siRNA/ALR-treated cells (Figure 3b).
Nuclear identiﬁcation, evidenced by TO-PRO-3, and the
speciﬁc clusterin immunodetection, evidenced by Alexa Fluor
488, are reported.
ROS levels. Figure 4 reports the level of ROS determined by
the GFER siRNA treatment and the protective effect
of rALR when it was introduced into the culture medium.
A statistically signiﬁcant (P¼1.1 10
 4) increase of 44-fold
of the ROS was present in siRNA/ALR-treated cells
compared with control cells. The presence of increasing
doses of rALR (1–100ng/ml) in the culture medium
counteracted the siRNA/ALR-induced oxidation in a dose-
dependent way.
Apoptotic gene expression. Figure 5 reports the effect of
GFER siRNA treatment on the expression of apoptotic
genes, bcl-2 and bax (Figure 5a), caspase-9 (Figure 5b)
and activated caspase-3 (Figure 5c) in siRNA/ALR-treated
and control glioma cells. The western blot analysis of bcl-2
and bax (Figure 5a) showed a signiﬁcant reduction of bcl-2
expression in siRNA/ALR-treated cells, compared with
control cells, without a notable variation of bax between the
two experimental conditions. The densitometric analysis of
the bcl-2 signals, normalized to b-actin expression,
demonstrated that the bcl-2 expression was signiﬁcantly
reduced in siRNA/ALR-treated cells (P¼4.1 10
 5).
Figure 5b reports caspase-9 expression revealing its
increase in siRNA/ALR-treated cells, compared with control
cells. The densitometric analysis, normalized to b-actin,
revealed this variation statistically signiﬁcant (P¼1.4 10
–3).
Figure 5c reports the expression of activated caspase-3.
An increase was detected in siRNA/ALR-treated cells,
compared with control cells, and the densitometric analysis
of the protein-related signals, normalized with that of the
b-actin, revealed the increase statistically signiﬁcant
(P¼1.3 10
 5).
Cytoﬂuorimetric analysis. Figure 6 reports the
cytoﬂuorimetric analysis of siRNA/ALR-treated and control
glioma cells. In the upper part of the ﬁgure (Figure 6a), the
biparametric histograms LOG FL1 versus LOG FL4 are
reported, distinguishing four cell populations: the viable cells
(low FITC and low 7-AAD), the secondary necrotic cells (high
FITC and high 7-AAD), the early apoptotic cells (high FITC
and low 7-AAD) and a possible fourth cell population
corresponding to the damaged viable cells (low FITC and
high 7-AAD). An increase in the percentage of early apoptotic
cells was observed in the culture of siRNA/ALR-treated
glioma cells and the comparison of the data from three
different experiments (Figure 6b) revealed a statistically
different (P¼1.9 10
 8) percentage of Annexin V
þ cells in
the culture of siRNA/ALR-treated cells (40.72±3.5)
compared with the percentage of Annexin V
þ cells
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Figure 1 EffectofrALRtreatmentonH2O2-inducedROSlevelsongliomacells.
Human T98G glioma cells, treated with H2O2, were incubated with different
concentrations of rALR (1–100ng/ml). The means±S.D. of six triplicate
independent experiments are shown
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Cell Death and Diseasedetected in the culture of control cells (5.63±1.55). No
necrotic or damaged cells were detected in any evaluation.
Electron microscopy (EM) analysis. Figures 7 and 8 report
the analysis, performed via EM, of control glioma (Figure 7)
and siRNA/ALR-treated cells (Figure 8). The control cells
appear elongated with peripheral cytoplasmic expansion and
the nuclei contain ﬁnely aggregated chromatin (down-left
inset) and voluminous nucleoli (arrows). The cytoplasm
contains numerous mitochondria of normal appearance
(up-right inset). Instead, the siRNA/ALR-treated cells
present a more abundant cytoplasm with degenerated
organelles. The nuclei are extremely irregular and the
mitochondria appear swollen or fragmented (down-right
inset). The cells present electron-dense granules
resembling lysosome structures (up-left inset). Vacuolar
dilatations of the endoplasmic reticulum are present (arrows).
Discussion
More than 10 years ago, our group identiﬁed a new protein,
the ALR,
5,19 initially known as HSS,
20 which increases
hepatocyte proliferation when administered to liver cells
already primed to proliferate;
21 the exact role of ALR in the
cellular metabolism is still not well deﬁned. Only recently,
some of the metabolic functions of ALR have been revealed
by in vivo and in vitro
10–15 experiments. In a recent study, in
partially hepatectomized rats,
10 we demonstrated a rapid
increase of ALR in the regenerating liver in the ﬁrst 6–12h
after the surgery, which favours the anti-apoptotic gene
expression, a molecular event, at this time of the regenerative
process, crucial for the sustention of liver-mass recovery after
the surgery.
9,22 In the same study, we identiﬁed two ALR
protein isoforms, with molecular weights of 21 and 23kDa,
respectively:
10 the 21-kDa form signiﬁcantly increased after
partial hepatectomy(PH),supportingthe notion thatthiscould
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Figure 2 Effect of siRNA/ALR treatment on ALR expression. ALR expressionin siRNA/ALR-treated and control human T98G glioma cells, determined using western blot
analysis (a) and confocal microscopy (b, green colour), are reported. The data shown are means±S.D. from ﬁve independent experiments
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Cell Death and Diseasebe the ALR protein form that actively participates in the
regenerative process after PH, whereas the 23-kDa form
remains unchanged. This latter molecular form of ALR has
been predominantly recognized in the mitochondrial IMS
23
where it is involved (i) through its FAD molecule
24,25 in the
electron pathway, with cytochrome-c
25 and the Mia40
26 as
physiological partners and (ii) in the maturation of cytosolic
Fe/S proteins.
27 Moreover, for the ﬁrst time in vivo,w e
demonstrated the anti-oxidative capacity of ALR, a biological
effect achieved by the induction of clusterin, a secreted
chaperone capable of maintaining the physiological cellular
redox state.
28
In our experiments, as other investigators,
4,10,12,14,15,29 we
used a small 15-kDa recombinant form of ALR that, mainly
reported as an extracellular cytokine,
12,26 represents the
smallest yet functional protein capable of participating in
the intracellular redox-dependent signalling pathways.
12
Indeed, the small 15-kDa ALR form, similarly to other ALR
homologous proteins identiﬁed in all organisms from viruses
tomammals,
6maintainsawellconservedamino-aciddomain,
CxxC, at the C-terminus part of the molecule, responsible for
its sulfhydryl oxidase enzymatic activity.
4,24–27 All these
proteins have different molecular weight and cytoplasmic
localization, but probably all support similar biological func-
tions as has been reported for some.
4,23–27 It is noteworthy to
underscore the fact that the most important signal structures
for the interactions and subcellular distribution of ALR are
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Figure 3 Effect of siRNA/ALR treatment on clusterin expression. Clusterin
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Figure 4 Effect of siRNA/ALR treatment on ROS levels expressed by glioma
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Cell Death and Diseaselocated at the C-terminal domain of the protein and not at the
N-terminal domain.
23–26
An additional ﬁnding that can help for the identiﬁcation of
the role of ALR in the cellular metabolism comes from in vitro
studies. Analyzing the H2O2-induced apoptotic process in
human-derived neuroblastoma cells, we demonstrated that
the addition of rALR in the culture medium normalizes LPO,
protein carbonylation and mitochondrial membrane perme-
abilityalteredbythepresenceofH2O2.
12All theseparameters
are typical of the mitochondrial apoptosis.
Furthermore, we demonstrated that ALR supports the
OXPHOS and ATP production in mitochondria isolated
from intact liver of rat intraperitoneally treated with rALR;
these effects are achieved by (i) the induction of mtTFA, a
mitochondrial DNA regulatory factor, and (ii) the upregulation
of mitochondrial gene expression.
30
In the present study, we tested the effect of ALR gene-
silencing (GFER) on the cell morphology, mitochondrial
apoptosis and cellular redox state of human-derived glioma
cells, T98G, maintained in culture. The data obtained
demonstrated a signiﬁcant reduction of ALR protein in
siRNA/ALR-treated cells (Figures 2a and b) and, as a
consequence, (i) a decrease of clusterin expression (Figures
3a and b), an increase of (ii) ROS levels (Figure 4) and (iii) the
apoptotic process, evaluated by bcl-2, bax (Figure 5a),
caspase-9 (Figure 5b), activated caspase-3 protein expres-
sion (Figure 5c) and the number of the apoptotic cells
(Figure 6). The induction of these biological events sufﬁciently
justiﬁesthecellularmorphologicalalterationsevidencedinthe
GFER-silenced glioma cells (Figure 8) compared with control
cells (Figure 7). In addition, we demonstrated that the
presence of increasing concentrations of rALR into the culture
medium of siRNA/ALR-treated cells abolished, almost totally,
the increased level of ROS induced by the siRNA/ALR
treatment (Figure 4). As mentioned before, we already
reported the beneﬁcial effects of ALR on the cell redox state
and on apoptosis.
10
To efﬁciently collocate these data within the cell meta-
bolism, some important considerations are necessary. The
devastating effect on cell metabolism of ROS increase,
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Cell Death and Diseaseassociated to the induction of apoptosis, has been unan-
imously reported under many experimental conditions.
17,31
It is known that the ‘oxidative stress’ can cause DNA, protein,
and/or lipid damage, leading to changes in chromosome
stability, genetic mutation, and/or modulation of cell growth
that may result in cancer.
32 Recent data underlined the strong
relationship between increased ROS levels and neoplastic
transformation, attributing them the role of critical signalling
molecules in cancer cells as well as in metastatic cells.
33
Indeed, such a state has been shown to regulate both genetic
and epigenetic cascades, and mutation studies have sug-
gested that chronic oxidative stress, particularly from chronic
inﬂammation, is associated with carcinogenesis.
34 For
example, ulcerative colitis has long been linked with a high
incidence of colorectal cancer and chronic gastritis due to, for
instance,theinfectionwithHelicobacterpylori,withthegastric
cancer,
34 as well as HCC in patients affected by CH. Most of
these pathological conditions are associated with high ALR
serum levels.
8
Various reports reveal a defective or inefﬁcient apoptosis
of cancer cells,
16,35,36 which renders almost ineffective any
pharmacological treatment of human neoplasia.
17 Thus, the
identiﬁcation of a mechanism that can weaken the apoptosis-
resistance strategy of cancer cellsisimperative to unravel novel
drugtargetsforthedesignofmoreeffectiveandtarget-selective
therapeutic strategies. For instance, in an in vivo mouse
xenograft study recently reported by Lin, co-administration of
the anti-oxidant agent resveratrol,and conventional chemother-
apy reduces brain tumour volumes by inducing cell apoptosis.
37
With this perspective, the increased apoptosis of glioma
cells, reported here by us, related to the GFER decreased
expression, could constitute an important and sufﬁcient
biological event to improve the effectiveness of the conven-
tional, sometimes inefﬁcient, chemotropic agents.
In addition, the present data, together with our previous
observations
10,12 and the data present in the literature,
11,13–15
strongly persuade us that ALR not only supports cell survival by
its anti-apoptotic effect but also holds the crucial function of an
anti-oxidative agent sustaining the levels of reducing agents
such asclusterin. It isnot easyto determinethe exact sequence
of these two metabolic events induced by ALR; we can only
state that, at least in partially hepatectomized rats, ALR
increases in the ﬁrst 6–12h after surgery, favouring
the anti-apoptotic event which occurs, in the same period of
the regenerative process, in the liver. More data are necessary
to resolve the aspects of the physiological role of ALR.
In conclusion, the present ﬁndings suggest that ALR could
be considered as a potential new target for the chemotherapic
treatment of gliomas and, considering the presence of ALR in
all eukaryotic cells,
6–14 and even in the viruses
38 we can
hazard to say that it could be a possible support for the
treatment of all human neoplasia. To our knowledge, with the
data present in the literature, we cannot consider the ALR as
an oncogene; we can only state that ALR is a factor
overexpressed in all neoplasia so far studied
8,14 and that for
the exact deﬁnition of its role in the carcinogenesis, more
studies are necessary. It is interesting to note that an ALR-KO
mouse strain is not yet available, probably because the
downregulation of GFER is not consistent with the cell
survival.
Materials and Methods
Reagents. rALR expressed in transfected COS-1 cells has been produced by
the Laboratory of Biochemistry and Molecular Biology (University of Georgia,
Athens, GA, USA). In line with other investigators, in the present experiments, we
used a rALR form of 15kDa, containing the well-conserved, biologically active, C-
terminaldomainofthemolecule.
29,30,39Allthechemicalreagentswerepurchased,if
not speciﬁcally reported, from Sigma-Aldrich (Milan, Italy). The polyclonal antibody
against ALR (MultiBind GmbH, Cologne, Germany; a gift from Dr. Thomas
Lisowsky) has already been employed for speciﬁc identiﬁcation of ALR.
7,10,12 For
raising the ALR antibody, a puriﬁed hexahistidinyl-tagged carboxyl-terminal
fragment of ALR (residues 81–205) was used.
7
Cellline. Human-derivedT98Ggliomacells(InterlabCellLineCollection,Genoa,
Italy) were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Sigma-Aldrich)
supplemented with 10% (v/v) inactivated FBS (PAA Laboratories GmbH, Pasching,
Austria), 2mM L-glutamine (Sigma-Aldrich), 100mg/ml penicillin and 100mg/ml
streptomycin (Sigma-Aldrich,) at 371Ci n5 %C O 2.T h ec e l l s ,g r o w nt o7 0 %
conﬂuence and treated for 48h, have been then trypsinized or treated as requested by
the different protocol of the experiments and the biological parameters evaluated.
RNA interference. For the RNA interference experiments, the speciﬁc pre-
designed siRNA (50-GGAGUGUGCUGAAGACCUATT-30; Applied Biosystems/
Ambion, Austin, TX, USA), targeting the mRNA of the human GFER gene, was
transfected, according to the manufacturer’s protocol, in T98G glioma cells using
siPORT NeoFX Transfection Agent (Applied Biosystems/Ambion). Silencer
Negative Control 1 siRNA AM4635 (Applied Biosystems/Ambion) with no
signiﬁcant similarity to human, mouse or rat gene sequences was used as
negative control.
H2O2-induced oxidative stress. Oxidative stress in human T98G glioma
cellswascausedbytheadditionofH2O2(Sigma-Aldrich)toculturemedium.Priorto
eachexperiment,H2O2wasfreshlypreparedfrom30%stocksolution.Todetermine
the most appropriate conditions for our experiments, different concentrations
of H2O2 (50, 100 and 200mM) were initially used (data not reported). Based on the
data obtained using the different H2O2 concentrations in our previous experiments
with neuroblastoma cells
12 and on the references reported in the literature,
40 in the
present study, we decided to use H2O2 at a concentration of 100mM. Culture cells
maintained in DMEM supplemented with 10% (v/v) inactivated FBS and without
H2O2 were used as control.
rALR treatment. With the purpose to test the ALR capacity to counteract the
H2O2-induced apoptosis, rALR (from 1 to 100ng/ml) was added to the culture
medium of H2O2-treated glioma cells. The short form (15kDa) of ALR was used.
This molecule corresponds to the physiologically active protein that was originally
identiﬁed and isolated by us
5 and whose biological activity has been demonstrated
in the majority of the experiments. Indeed, most independent scientiﬁc publications
from a large number of research groups have used the 15-kDa ALR variant for their
experiments
4,10,12,14,15,29andthisisnowthegeneralstandard,inALRexperiments,
tohavecomparabledata.T98Gcells,maintainedinDMEMsupplementedwith10%
(v/v) inactivated FBS were used as control. The rALR treatment was done, at least,
three times for each experimental protocol.
ALR expression
Western blot analysis. Human T98G glioma cells were grown in 75-cm
2 ﬂasks
in DMEM supplemented with 10% FBS and in the presence (siRNA/ALR-treated
cells) or absence (control cells) of GFER-speciﬁc siRNA. Cytosolic protein
preparation and subsequent electrophoresis were done following a standard
procedure.
12 Brieﬂy, after 48h of incubation, 2 10
6 glioma cells were trypsinized
(Trypsin0.05%/EDTA0.02%;M-Medicalsrl,Milan,Italy),addedwith200mlofRIPA
buffer (Sigma-Aldrich), containing protease inhibitors (protease-inhibitor cocktail
tablets 1 , Roche Applied Science, Milan, Italy) and anti-phosphatases (sodium
orthovanadate 2mM; Sigma-Aldrich), gently stirred, centrifuged for 20min at
14000 g at 41C and the supernatant collected. Protein concentration was
evaluated using the Bradford assay (Bio-Rad Laboratories, Milan, Italy). Aliquots of
20mg of total proteins were separated on 4–12% sodium dodecyl sulphate-
polyacrylamide gels(Invitrogensrl),transferredontoanitrocellulosemembraneand
then probed with primary antibody speciﬁc for ALR, diluted 1:200 in a blocking
solution(5%ofnon-fatdrymilk)(Bio-RadLaboratories)inTBS-T(TrisBufferSaline-
Tween 20). The primary antibody was identiﬁed by an HRP-conjugated secondary
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chemiluminescent substrate of HRP (Pierce Biotechnology, Inc., Rockford, IL,
USA). To detect the b-actin housekeeping protein, the membranewas washed with
the Restore Western Blot Stripping Buffer (Pierce Biotechnology, Inc.) for 15min
and reprobed with the anti-b-actin primary antibody diluted 1:500 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA), subsequently identiﬁed by an HRP-
conjugated secondary antibody diluted 1:20000 (Bio-Rad Laboratories) and
detected by a chemiluminescent substrate of HRP (Pierce Biotechnology, Inc.) as
for ALR detection. The densitometric analysis of each protein-related signal was
obtained using the Molecular Imager Chemidoc (Bio-Rad Laboratories) and
normalized against b-actin expression.
Confocal microscopy. Human T98G glioma cells were grown, for 48h, onto
cover glasses, maintained in petri dishes in DMEM added with 10% FBS in
presence (siRNA/ALR-treated cells) or absence (control cells) of GFER-speciﬁc
siRNA.Thecoverglasseswerethenpulledoutfromthedishesandﬁxedin4%PFA
(Sigma-Aldrich) in PBS for 15min and washed with PBS. The cells were then
permeabilizedby0.25%TritonX-100(Sigma-Aldrich)for20min.Afterthreewashes
with PBS, nonspeciﬁc protein binding was inhibited by a blocking solution (5% of
FBS and 3% BSA) (Sigma-Aldrich) in PBS for 2h. The cells were then incubated
overnight at 41C with the anti-ALR antibody diluted 1:200 in the blocking solution.
A negative control was performed treating different cover glasses with the blocking
solutionshortoftheALR-speciﬁcprimaryantibody.Thecellswerethenwashedwith
PBS and incubated with the Alexa Fluor 488 secondary antibody (Invitrogen srl)
diluted 1:200 and with TO-PRO-3 (Invitrogen srl) diluted 1:7000 in PBS for 20min
for nuclear staining. The cover glasses were then mounted with Fluoromount K024,
an anti-fading agent (Diagnostic BioSystems, Pleasanton, CA, USA), and analyzed
with the confocal microscope Leica TCS SP2 (Leica Microsystems, Wetzlar,
Germany).Toverifythespeciﬁcityoftheimmunoreaction,appropriatecontrolswere
performed incubating the cells with only the secondary antibody or using the pre-
immune rabbit serum as primary antibody. We repeated the experiments three
times. The green colour identiﬁes ALR immunodetection and the blue colour
identiﬁes the nuclei.
Clusterin expression
Western blot analysis. Cytosolic protein preparation and subsequent protein
electrophoresis were done as described for ALR western blot analysis. The
nitrocellulose membrane, with the transferred proteins, were probed with a primary
antibody speciﬁc for clusterin (Santa Cruz Biotechnology, Inc.) diluted 1:200 in
blocking solution, subsequently identiﬁed by an HRP-conjugated secondary
antibody (Bio-Rad Laboratories) and ﬁnally detected by a chemiluminescent
substrate of HRP (Pierce Biotechnology, Inc.) and normalized to b-actin signal.
Clusterin and b-actin densitometric expression was determined by the Molecular
ImagerChemidoc(Bio-Rad Laboratories) as referred for ALR western blot analysis.
The evaluation was done at least three times.
Confocal microscopy. Human T98G glioma-cell preparation for clusterin
immunoﬂuorescence detection was performed as described for ALR
immunoﬂuorescence detection. The cells, grown on cover glasses, were incubated
with the anti-clusterin antibody (Santa Cruz Biotechnology, Inc.), diluted 1:200 in the
blockingsolution,overnightat41C.Anegativecontrolwasperformedtreatingdifferent
cover glasses with the blocking solution short of the clusterin-speciﬁc primary
antibody. The cells were then washed with PBS and incubated with an Alexa Fluor
secondary antibody (Invitrogen srl) diluted 1:200 and with TO-PRO-3 (Invitrogen srl)
diluted 1:7000 in PBS for 20min for nuclear staining. The cover glasses were then
mounted with Fluoromount K024 and analyzed with the confocal microscope Leica
TCS SP2 (Leica Microsystems, Wetzlar, Germany). To verify the speciﬁcity of the
immunoreaction,appropriatecontrolswereprepared,incubatingthecellswithonlythe
secondary antibody or using the pre-immune rabbit serum as primary antibody. The
green colour identiﬁes clusterin immunodetection and the blue colour identiﬁes the
nuclei. We repeated the experiments at least three times.
ROS generation. ROS generation was monitored using an oxidation-sensitive
ﬂuorescent probe DCFH-DA (Sigma-Aldrich). Non-ionic, non-polar DCFH-DA
crosses cell membranes and is hydrolyzed by intracellular esterases to the
nonﬂuorescent (DCFH), which can be rapidly oxidized to the highly ﬂuorescent 2,
7-dichloroﬂuorescein in the presence of ROS. In all, 5 10
5 siRNA/ALR-treated or
control T98G cells per well were plated into sterile black Culture Plate 96-F wells
(PerkinElmer, Life andAnalytical Sciences,Inc, Waltham,MA, USA). After48h, the
cells were incubated (or not) with a ﬁnal 100mMH 2O2 per well in DMEM and
incubated for 10min at 371Ci n5 %C O 2. Then the cells were washed twice with
PBS and incubated for 4h at 371Ci n5 %C O 2 with different concentrations of rALR
(1–100ng/ml). Subsequently, the culture medium was removed and cells were
incubated with 0.1mM DCFH-DA in DMEM at 371Ci n5 %C O 2 in the dark for an
additional 30min and then washed thrice with PBS. Fluorescence intensity was
measured directly in each well at an excitation wavelength of 485±20nm and an
emission wavelength of 530±25nm using the multiwell ﬂuorescence plate reader
Wallac Victor mod.1421 (PerkinElmer).
Apoptotic gene expression. Bax, bcl-2, caspase-9 and activated caspase-
3 protein expression were evaluated using western blot analysis on nitrocellulose
membranespreparedasreportedforALRwesternblotanalysis.Eachnitrocellulose
membrane was probed with the primary antibody speciﬁc for bax or bcl-2 (Santa
Cruz Biotechnology, Inc.), or for caspase-9 (Santa Cruz Biotechnology, Inc.) or
activated caspase-3 (Abcam Ltd, Cambridge, UK), all diluted to 1:200 in the
blocking solution. The primary antibody was then identiﬁed by an HRP-conjugated
secondary antibody (Bio-Rad Laboratories) diluted 1:20000, which was
subsequently detected by a chemiluminescent substrate of HRP (Pierce
Biotechnology, Inc.). Each protein-related electrophoretic band was evaluated as
referred for ALR western blot analysis and the densitometric value normalized with
b-actin protein signal. Each analysis was done ﬁve times.
Flow-cytometric detection of apoptotic cells. Annexin V-FITC/7-AAD
Kit PN IM3614 (Beckman Coulter, Milan, Italy) was used to detect apoptosis on
siRNA/ALR-treated or control T98G cells, grown in 75-cm
2 ﬂasks in complete
medium (DMEMþ10% FBS). After 48h, the cells were trypsinized (trypsin 0.05%/
EDTA 0.02%) (M-Medical srl), washed with cold PBS and then centrifuged and
resuspended in cold 1  binding buffer to 5 10
6 cells/ml. Ten ml of annexin
V-FITC solution and 20 ml of AAD viability dye were then added to 100ml of the cell
suspensions and the mixture was kept on ice for 15min in the dark. Subsequently,
400mlo f1  binding buffer was added and gently mixed. The cell preparation was
then analyzed by Cytomics FC500 (Beckman Coulter) ﬂow cytometry within 30min.
The average of the different cell populations was determined using siRNA/ALR and
control cells from, at least, three different experiments.
EM. siRNA/ALR-treated or control T98G cells, maintained in 75-cm
2 ﬂasks in
complete culture medium (DMEMþ10% FBS) for 48h, were trypsinized (trypsin
0.05%/EDTA 0.02%; M-Medical srl) and then ﬁxed in a mixture of 3% PFA and 1%
glutaraldehyde in 0.1M PBS at pH 7.4 for 5h at 41C. Subsequently, the cells
were postﬁxedin 1% OsO4 in PBS for 30min at 41C, washedin severalchanges of
PBS, dehydrated in graded alcohols and embedded in Epon-Araldite (TAAB,
Reading, UK). Semi-thin sections (1mm thick) were heat-stained with toluidine blue
borate. Ultra-thin sections for EM were mounted on formvar-coated nickel grids and
stained routinely with uranyl acetate and lead citrate. The grids were observed
under a Morgagni 268 electron microscope (FEI, Hillsboro, OR, USA).
Statistical analysis. The results obtained are expressed as mean±S.D.
Statistical comparison among groups was determined using analysis of variance.
Where indicated, individual comparisons were performed using Student’s t-test.
Statistical signiﬁcance was ascribed to the data when Po0.05. If not speciﬁcally
reported, each datum is representative of at least three different and separated
experiments.
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